Business Wire

WA-AMAZON.COM

3.11.2022 12:09:44 CET | Business Wire | Press release

Share
Amazon and USAID Launch Effort to Boost Climate Funding for Women

Amazon and the U.S. Agency for International Development (USAID) are launching a public-private partnership to address the gender inequities that exist for women in the climate finance ecosystem and support female entrepreneurs with the resources they need to accelerate climate change innovations.

Amazon will commit a total of $53 million to help accelerate women’s climate solutions, including $3 million toward the USAID partnership and $50 million for Amazon to invest directly in climate tech companies run by women.

Amazon will serve as a founding partner of USAID’s Climate Gender Equity Fund, a new climate finance facility designed to remove systemic market barriers that prevent women and girls from accessing climate finance. USAID will also match Amazon’s $3 million investment to help launch the fund.

The Climate Gender Equity Fund will have a global focus and provide grants for businesses, NGOs, accelerators, incubators, and grassroots organizations working on women-led climate solutions. It also will fund efforts to help women access the networks and technical skills they need to accelerate the development of their climate change technologies.

As a co-founder of The Climate Pledge, a commitment to reach net-zero carbon emissions by 2040, Amazon will work with Pledge signatories and other companies to encourage their additional support and corporate investment in this new fund. The partnership will help advance mutual goals around women’s climate leadership and gender equity, including Amazon’s sustainability goals, the work of The Climate Pledge, and the Biden administration’s National Strategy on Gender Equity and Equality.

Additionally, Amazon is allocating $50 million from its Climate Pledge Fund to invest in women-founded and women-led climate tech companies, as well as incubators and accelerators that prioritize women-led entities. The Climate Pledge Fund–Amazon’s venture capital program that invests in companies pioneering decarbonizing technologies and solutions–will collaborate with USAID and the Climate Gender Equity Fund to source new investment opportunities and broaden its pipeline of female applicants.

“As an important step in solving climate change, we must address the gender inequalities that persist in climate finance, and ensure female entrepreneurs have an equal seat at the table and access to the funding, networks, and technical support they need to scale climate solutions,” said Kara Hurst, vice president of Worldwide Sustainability at Amazon. “We’re proud to collaborate with USAID and the Biden administration to help scale women-led climate solutions globally. This is just one part of our broader Climate Pledge goal to reach net-zero carbon by 2040, and we encourage other companies to join us in this effort.”

Female-founded companies typically receive a fraction of global venture capital, and that percentage fell during the pandemic. However, research shows that female entrepreneurs are more likely than their male counterparts to innovate to address social needs. Women-led companies also generate more revenue per dollar invested and produce greater ROI for investors.

Amazon has recently taken several additional steps to advance gender equality across its value chain, including:

  • Committing to the United Nations Women's Empowerment Principles (WEPs), which offer businesses guidance on ways to promote gender equity and empower women in the workplace, marketplace, and community.
  • Granting $1 million to the Resilience Fund for Women in Global Value Chains, which is investing in organizations supporting women in global value chains, including manufacturing, apparel, and agriculture, with a focus on gender-based violence and reproductive health.
  • Partnering with BSR’s HERproject to combat gender-based discrimination in China, Bangladesh, Vietnam, and India by engaging suppliers, factory workers, and management. These efforts have reached nearly 10,000 women.
  • Investing in the Elevate Future Fund, which increases funding to women and other underrepresented founders working on climate tech solutions, as well as firms creating economic opportunity for distressed and disadvantaged communities. This investment is part of the new Amazon Catalytic Capital initiative to provide underrepresented entrepreneurs with access to capital.
  • Collaborating with Greentown Labs, North America’s largest climate tech incubator, to source and engage with new startups. The Climate Pledge Fund participates in pitch events, including “Access to Success,” a community event for diverse founders. Amazon also serves on Greentown Labs’ Industry Leadership Council.
  • Working with Elemental Excelerator, a climate tech startup accelerator that is a leader in promoting diversity, equity, and inclusion principles in climate tech. Elemental Excelerator recently launched an Equity & Access program that helps startup founders build equity into their organizations’ teams and activities.

Learn more about Amazon’s sustainability efforts.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005180/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye